MedTrace Logo

New Strategy to Predict Early Sepsis

NCT04118179 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-06-05

No results posted yet for this study

Summary

This is an observational prospective multicentre study on patients attending the emergency department and suspected to have sepsis. Blood markers characteristic of a Cellular Reprogramming (CR) signature and predicting severe sepsis and organ failure will be measured and validated.

Conditions

Interventions

OTHER

Blood sample collection

A blood sample (1 tube) will be collected for the analysis of the CR signature.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Robert E Hancock, PhD · University of British Columbia

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States
  • Australia
  • Canada
  • Colombia
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118179 on ClinicalTrials.gov